| First Author | Umeda M | Year | 2021 |
| Journal | Proc Natl Acad Sci U S A | Volume | 118 |
| Issue | 18 | PubMed ID | 33911034 |
| Mgi Jnum | J:309162 | Mgi Id | MGI:6707787 |
| Doi | 10.1073/pnas.2023230118 | Citation | Umeda M, et al. (2021) ADAM9 enhances Th17 cell differentiation and autoimmunity by activating TGF-beta1. Proc Natl Acad Sci U S A 118(18):e2023230118 |
| abstractText | The a disintegrin and metalloproteinase (ADAM) family of proteinases alter the extracellular environment and are involved in the development of T cells and autoimmunity. The role of ADAM family members in Th17 cell differentiation is unknown. We identified ADAM9 to be specifically expressed and to promote Th17 differentiation. Mechanistically, we found that ADAM9 cleaved the latency-associated peptide to produce bioactive transforming growth factor beta1, which promoted SMAD2/3 phosphorylation and activation. A transcription factor inducible cAMP early repressor was found to bind directly to the ADAM9 promoter and to promote its transcription. Adam9-deficient mice displayed mitigated experimental autoimmune encephalomyelitis, and transfer of Adam9-deficient myelin oligodendrocyte globulin-specific T cells into Rag1 (-/-) mice failed to induce disease. At the translational level, an increased abundance of ADAM9 levels was observed in CD4(+) T cells from patients with systemic lupus erythematosus, and ADAM9 gene deletion in lupus primary CD4(+) T cells clearly attenuated their ability to differentiate into Th17 cells. These findings revealed that ADAM9 as a proteinase provides Th17 cells with an ability to activate transforming growth factor beta1 and accelerates its differentiation, resulting in aberrant autoimmunity. |
